SCHEMBL29639017

SCHEMBL29639017

CS(=N)(=N)C[C@@H](Cc1ccccc1)C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.66
CPA1 P15085 7/20 0.58
CPA3 P15088 3/20 0.58
FOLH1 Q04609 3/20 0.58
CPB1 P15086 1/20 0.58
CPB2 Q96IY4 1/20 0.58
SLC1A3 P43003 1/20 0.53
SLC1A2 P43004 1/20 0.53
SLC1A1 P43005 1/20 0.53
MME P08473 1/20 0.50
NAALAD2 Q9Y3Q0 1/20 0.49
ANPEP P15144 1/20 0.48
RNPEP Q9H4A4 1/20 0.48
DNPEP Q9ULA0 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17813735 1.00 CYP1A2 (0.66) CYP1A2CPA1CPA3FOLH1CPB1
SCHEMBL7325595 0.86 CYP1A2 (0.66) CYP1A2CPA1CPA3FOLH1CPB1
SCHEMBL7322955 0.82 CYP1A2 (0.66) CYP1A2CPA1CPA3FOLH1CPB1
SCHEMBL7322961 0.82 CYP1A2 (0.66) CYP1A2CPA1CPA3FOLH1CPB1
SCHEMBL7322967 0.82 CYP1A2 (0.66) CYP1A2CPA1CPA3FOLH1CPB1
SCHEMBL4664822 0.80 CYP1A2 (1.00) CYP1A2CPA1CPA3FOLH1CPB1
SCHEMBL7332196 0.79 CYP1A2 (0.61) CYP1A2CPA1CPA3FOLH1CPB1
SCHEMBL7348130 0.79 CYP1A2 (0.61) CYP1A2CPA1CPA3FOLH1CPB1
SCHEMBL7332201 0.79 CYP1A2 (0.61) CYP1A2CPA1CPA3FOLH1CPB1
SCHEMBL7348126 0.79 CYP1A2 (0.61) CYP1A2CPA1CPA3FOLH1CPB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122067596-A Human organ aging evaluation and analysis method, equipment, medium and product 张云鹏 2026-05-19 CN disclosed
US-20250378952-A1 METHODS FOR DETERMINING MENSTRUAL CYCLE TIME POINT THE UNIVERSITY OF MELBOURNE (AU) 2025-12-11 US disclosed
US-20240327918-A1 A BASELINE GENE EXPRESSION-BASED PROGNOSTIC FOR ANTI-INF ALPHA THERAPY RESPONSE NI PATIENTS WITH INFLAMMATORY BOWEL DISEASE INFLAMMATIX, INC. (US) 2024-10-03 US disclosed
US-20230302035-A1 REPEAT RNA AS BIOMARKERS OF TUMOR IMMUNE RESPONSE THE GENERAL HOSPITAL CORPORATION 2023-09-28 US disclosed
US-20220204971-A1 Compositions and Methods for Inhibiting Cancers and Viruses ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2022-06-30 US disclosed